GlassScriptPhysician profile
Christina L Mitchell
NPI 1316013105
$314,545.29
in general payments reported to CMS, 2019-2025
40 companies · $153K in 2025
The $153K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $768 · 2021: $1,186 · 2022: $27K · 2023: $44K · 2024: $88K · 2025: $153K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $273K · Food and Beverage: $8,608 · Travel and Lodging: $2,726 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $272,860.50 |
| Food and Beverage | $8,608.43 |
| Travel and Lodging | $2,726.11 |
| Education | $366.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $155,172.01 | 2019-2025 | Dupixent |
| Genzyme Corporation | $151,973.30 | 2021-2025 | |
| Abbvie INC. | $1,160.81 | 2019-2025 | |
| Janssen Biotech, INC. | $1,022.87 | 2020-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $777.28 | 2022-2024 | Sotyktu |
| Amgen INC. | $708.59 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $597.10 | 2019-2025 | |
| Ucb, INC. | $429.26 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $344.32 | 2021-2025 | Ilumya |
| Pfizer INC. | $289.15 | 2019-2024 | |
| Lilly USA, LLC | $202.09 | 2021-2025 | Ebglyss, Taltz, Zepbound |
| Galderma Laboratories, L.P. | $194.10 | 2019-2024 | |
| Journey Medical Corporation | $185.65 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $145.57 | 2024-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $133.86 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.